Montelukast Cinfa (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, E4 and related molecules from triggering bronchial smooth‑muscle contraction, mucus production and vascular leakage. This inhibition reduces airway narrowing and allergic inflammation.

The appropriate dose of Montelukast Cinfa is determined by the prescribing clinician based on the patient’s age, weight, condition severity and other medical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Montelukast in pregnancy are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the risk. Information on use while breastfeeding is also insufficient, so a risk‑benefit assessment is required.

To request Montelukast Cinfa, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who prefer a once‑daily tablet, but it may be less potent for acute symptom relief compared with inhaled bronchodilators.

Montelukast Cinfa should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency.

Montelukast Cinfa is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include rare allergic reactions such as angioedema or anaphylaxis, neuropsychiatric events like depression or suicidal thoughts, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Cinfa is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. Patients with a history of severe allergic reactions to leukotriene‑modifying agents should avoid this medication.